Global Radiopharmaceuticals in Nuclear Medicine Market: Size, Trends, and Opportunities The radiopharmaceuticals in nuclear medicine industry is witnessing robust expansion due to continuous advancements in diagnostic and therapeutic procedures. Increasing adoption of targeted therapies and precision medicine is reshaping the market dynamics across healthcare sectors globally. Market Size and Overview The global radiopharmaceuticals in nuclear medicine market size is estimated to be valued at USD 7.72 billion in 2025 and is expected to reach USD 13.85 billion by 2032, exhibiting a CAGR of 8.7% from 2025 to 2032. Radiopharmaceuticals in Nuclear Medicine Market Growth is driven by rising prevalence of chronic diseases, enhanced market scope for novel radiotracers, and expanding applications in oncology and cardiology. Increasing investments in research and development continue to influence the market forecast positively, reflecting strong market trends and steady market revenue growth across regions. Radiopharmaceuticals in Nuclear Medicine Market - https://www.coherentmarketinsights.com/market-insight/radiopharmaceuticals-market-70 #RadiopharmaceuticalsMarket #NuclearMedicine #TheranosticRadiopharmaceuticals #DiagnosticImaging #CoherentMarketInsights